

**Clean Copy of Amended Title:**

Ligand-Mediated Viral Delivery System for Gene Therapy

**Clean Copy of Added Abstract**

B1  
Viral vectors comprising a therapeutic agent are non-covalently bound directly to a cell-targeting ligand, such as transferrin. These vectors can be administered to a host animal to deliver the therapeutic agent to target cells within the host animal.

**Clean Copy of Amended Specification**

Page 6, 3rd paragraph should read:

B2  
Figure 6. Effect of the combination of systemically delivered, tumor-targeted adenoviral-p53 and chemotherapy (Taxotere® (TxT)) on MDA-MB-435 xenograft tumors *in vivo*.

**Clean Copy of Amended Claims**

B3  
Claim 1 (amended). A vector for delivery of a virus to a target cell within a host animal, comprising a cell-targeting ligand non-covalently bound directly to said virus.

B4  
Claim 17 (twice amended). A method for preparing a vector for the systemic delivery of a virus to a target cell, said vector comprising a cell-targeting ligand non-covalently bound directly to said virus, comprising mixing said cell-targeting ligand with said virus in an aqueous medium, whereby said ligand non-covalently binds directly to said virus.

B5  
Claim 19 (amended). A method for providing a nucleic acid therapeutic agent to an animal suffering from head and neck cancer, bladder cancer, breast cancer, thyroid cancer, ovarian cancer, prostate cancer, melanoma or lymphoma, comprising administering to said animal a therapeutically effective amount